Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06SDP
|
||||
| Former ID |
DPR000073
|
||||
| Drug Name |
Melanotetan II
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Sexual dysfunction; Obesity; Type 2 diabetes [ICD9: 250, 250.00, 250.02, 278, 302.7; ICD10:E08-E13, E11, E66, F52] | Preclinical | [1] | ||
| Company |
Clinuvel Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H17ClO6
|
||||
| Canonical SMILES |
CC1CC2C(O2)C=CC=CC(=O)CC3=C(C(=CC(=C3Cl)O)O)C(=O)O1
|
||||
| InChI |
1S/C18H17ClO6/c1-9-6-15-14(25-15)5-3-2-4-10(20)7-11-16(18(23)24-9)12(21)8-13(22)17(11)19/h2-5,8-9,14-15,21-22H,6-7H2,1H3/b4-2+,5-3-/t9-,14-,15-/m1/s1
|
||||
| InChIKey |
WYZWZEOGROVVHK-GTMNPGAYSA-N
|
||||
| CAS Number |
CAS 121062-08-6
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
811127, 831350, 6436135, 7890236, 12015279, 14716680, 16476901, 24899351, 26703315, 26717606, 34178996, 46391541, 46515660, 47211693, 49703995, 57570978, 58686944, 87323562, 87557234, 87557487, 87557647, 91722227, 104234190, 134339525, 134340418, 135055217, 135685860, 137865009, 140305216, 162223526, 170481460, 175607782, 208012627, 227138252, 241179499, 241182551, 241375519, 252457202, 252469187
|
||||
| Target and Pathway | |||||
| Target(s) | Melanocortin-4 receptor | Target Info | Agonist | [1] | |
| Melanocortin-3 receptor | Target Info | Agonist | [1] | ||
| KEGG Pathway | Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction | ||||
| Pathway Interaction Database | Syndecan-3-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (s) signalling eventsR-HSA-375276:Peptide ligand-binding receptors | |||||
| G alpha (s) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.